The Motley Fool
The Motley Fool's daily look at stocks in the news, as well as the top business and investing stories.
The Lollipop War Has Begun
Biogen falls 30% after halting trials for its Alzheimer’s drug. Healthcare analyst (and Industry Focus host) Shannon Jones discusses potential next moves for the suddenly-embattled pharmaceutical company. CVS starts selling cannabis products in eight states. Plus, a federal judge sides with the maker of Dum Dum lollipops in a battle against Tootsie Roll. Get $50 off your first job post at www.LinkedIn.com/Fool.
FedEx, Brexit, and Levi’s IPO
FedEx shares fall as it deals with Brexit, the threat of Amazon, and a whole lot more. MFAM Funds portfolio manager Bill Barker analyzes the near-term future for FedEx, as well as the latest results from General Mills. Plus, we discuss Levi’s impending IPO. (Tangents include competitive dock-jumping, breakfast cereals, and Bad Idea Jeans.)
The Challenges of Investing in Cannabis
Tilray reports a wider-than-expected loss but sales more than double. Should investors take stock in the Canadian cannabis producer? What’s the best way to invest in the cannabis space? Motley Fool analysts Andy Cross and Emily Flippen tackle those questions and talk Apple, Netflix, and the future of video. Thanks to LinkedIn for supporting The Motley Fool. Go to Linkedin.com/fooland get $50 off your first job post.
See More Episodes on Himalaya